Company Encyclopedia
View More
name
Entera Bio
ENTX.US
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism.
1.946 T
ENTX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking139/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-99.43%E
    • Profit Margin-8694.35%E
    • Gross Margin0.00%E
  • Growth ScoreB
    • Revenue YoY25.25%A
    • Net Profit YoY-17.47%D
    • Total Assets YoY124.87%A
    • Net Assets YoY136.11%A
  • Cash ScoreB
    • Cash Flow Margin-1.15%D
    • OCF YoY25.25%A
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio12.48%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates

    FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study ...

    GlobeNewswire·
    US
    ENTX
    +2.43%
    GlobeNewswire·
    US
    ENTX
    +2.43%

    Entera Bio | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ENTX
    +2.43%
    LB filings·
    US
    ENTX
    +2.43%

    Israel's Entera Bio Q3 net loss widens

    Entera Bio reported a Q3 2025 net loss of $3.2 million, with increased operating expenses. Cash reserves are expected to support operations through mid-2026. Research and development expenses rose slightly to $1.6 million. The sole analyst rating is "buy," with a median 12-month price target of $10.00, significantly above the current price of $2.74.

    Reuters·
    US
    ENTX
    +2.43%
    Reuters·
    US
    ENTX
    +2.43%

    Entera Bio reports Q3 net loss of $3.2 million

    Entera Bio Ltd. reported a Q3 net loss of $3.2 million, or $0.07 per share, compared to $3.0 million, or $0.08 per share, in Q3 2024. R&D expenses rose to $1.6 million due to regulatory and Phase 3 preparation for EB613. Cash and equivalents were $16.6 million, with $8.0 million restricted for OPKO collaboration. FDA agreed on primary and secondary endpoints for EB613 Phase 3 study. Progress on oral GLP-2 and OXM programs was noted. Cash expected to fund operations through mid-Q3 2026.

    Reuters·
    US
    ENTX
    +2.43%
    Reuters·
    US
    ENTX
    +2.43%

    Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Grows By 86.7%

    Entera Bio Ltd. (NASDAQ:ENTX) experienced a significant increase in short interest, rising 86.7% to 96,900 shares as of October 15th. This represents 0.2% of the stock being short sold, with a short-interest ratio of 0.5 days based on an average trading volume of 201,500 shares. Analysts have mixed ratings on the stock, with an average rating of "Moderate Buy" and a price target of $10.00. Entera Bio's stock opened at $2.91, with a market cap of $132.87 million and a P/E ratio of -11.19. Institutional investors hold 14.11% of the stock.

    Market Beat·
    US
    ENTX
    +2.43%
    Market Beat·
    US
    ENTX
    +2.43%
    © 2025 Longbridge｜Disclaimer